Yunnan Baiyao Posts Over 5.5 Billion Yuan in Core Series Sales for 2025, Marking 18% Growth

Deep News08-11

During a recent investor briefing, Yunnan Baiyao Group Co., Ltd. disclosed that its core product lineup, including aerosol sprays and adhesive plasters, achieved total sales revenue exceeding 5.5 billion yuan in 2025. This represents a year-on-year increase of more than 18%.

The company attributed this performance to a multi-pronged strategy. Firstly, it has aggressively expanded its online presence, precisely targeting the "immediacy" trend in O2O channels. By building a comprehensive "in-platform plus out-of-platform" synergy matrix, Yunnan Baiyao has strengthened its brand recognition and market competitiveness in the instant health consumption sector.

Secondly, a large-scale, systematic "big legion" strategy was deployed within its pharmaceutical business unit. This involved concentrating human resources and capital under unified policies to execute cross-provincial promotional campaigns.

Thirdly, the company implemented a content marketing system focused on scenario-based, professional, and youth-oriented approaches. By leveraging themes such as "trauma and pain relief," "sports companion," and "essential family medicine," Yunnan Baiyao utilized various platforms for comprehensive, integrated marketing that blends brand building, efficiency, and sales, effectively driving volume growth.

Furthermore, based on the current consumer age structure, the company is using these measures to actively ensure its products precisely reach consumers of different age groups, thereby continuously expanding its customer base.

Finally, guided by clinical value and driven by clinical academic research, Yunnan Baiyao is accelerating the secondary development and post-marketing reevaluation of key product varieties. Evidence-based research for flagship items like Yunnan Baiyao capsules, Yunnan Baiyao aerosol spray, and Yunnan Baiyao adhesive plaster is progressing steadily, paving the way for broader application scenarios.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment